An alternative approach for the development of a LF vaccine would be the use of reverse genetics to generate biologically contained versions of LASV in a similar way as described for Ebola virus (Halfmann et al., 2008) and influenza (Martinez-Sobrido and Garcia-Sastre, 2010).